Results 41 to 50 of about 1,436,444 (347)

Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides

Journal of Immunology Research, 2015
We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study.
Serkan Yazıcı, Emel Bülbül Başkan, Ferah Budak, Barbaros Oral, Şaduman Balaban Adim, Zübeyde Ceylan Kalin, Güven Özkaya, Kenan Aydoğan, Hayriye Saricaoğlu, Şükran Tunali   +9 more
doaj   +1 more source

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display

Journal of Translational Medicine, 2023
Background Monoclonal antibody (mAb)-based immunotherapies have achieved promising outcomes in the treatment of immunological and oncological indications. CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms.
Mahmoud Ganji, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh   +2 more
doaj   +1 more source

Plasmodium falciparum antigens on the surface of the gametocyte-infected erythrocyte. [PDF]

, 2008
BACKGROUND: The asexual blood stages of the human malaria parasite Plasmodium falciparum produce highly immunogenic polymorphic antigens that are expressed on the surface of the host cell.
Christopher J. Drakeley, Saeed Maha, Saeed, Maha, Alexander Neal, Saeed, M., Geoffrey A T Targett, Sutherland, Colin J, Drakeley Christopher J., Targett Geoffrey A. T., Roeffen Will, Geoffrey A. T. Targett, Colin J. Sutherland, Targett, Geoffrey AT, Alexander, N., Neal Alexander, Colin J Sutherland, Sutherland Colin J., Targett, G.A.T., Roeffen, W.F.G., Roeffen, Will, Maha Saeed, Alexander, Neal, Drakeley, Christopher J, Drakeley, C., Will Roeffen, Christopher J Drakeley, Sutherland, C.J.   +26 more
core   +2 more sources

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Cancer Journal, 2020
Dear Editor, CD19 chimeric antigen receptor T cell (CAR-T) therapy has achieved high response rates in patients with relapsed/ refractory acute lymphoblastic leukemia (R/R ALL).
Yi-Yun Wang, Ying-Ying Yang, Ruimin Hong, Hou-Li Zhao, Guo-Qing Wei, Wenjun Wu, Hui-Jun Xu, Jia-Zhen Cui, Yan-Lei Zhang, A. Chang, Yong-Xian Hu, He Huang   +11 more
semanticscholar   +1 more source

T cells expressing CD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells

Cancer immunology research, 2016
Bispecific chimeric antigen receptors (CARs) have been systematically optimized to simultaneously target two clinically relevant antigens, CD19 and CD20, presenting a clinically applicable solution to antigen escape and facilitating the rational design ...
Eugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, M. Jensen, Y. Chen   +4 more
semanticscholar   +1 more source

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj   +1 more source

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

Nature Communications
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target ...
Ming Shi, Jiao-Jiao Wang, Hong-Ming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhi-Ling Yan, W. Sang, K. Qi, De-Peng Li, F. Zhu, Zhen-Yu Li, J. Qiao, Qingyun Wu, Ling-Yu Zeng, Xiao-Ming Fei, Weiying Gu, Yu-Qing Miao, Kai-Lin Xu, Junnian Zheng, Jiang Cao   +21 more
semanticscholar   +1 more source

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

Journal of Immunotherapy for Cancer, 2017
BackgroundClinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse.
D. Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, A. Kaiser, B. Dropulić, R. Orentas   +8 more
semanticscholar   +1 more source

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. [PDF]

, 2011
Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL).
Graham P. Collins, Liggins, Amanda P., Liggins, AP, Lawrie, Charles H., Banham, Alison H., Pulford, Karen, Pulford Karen, Christopher D. O. Cooper, Cooper Christopher D. O., Christian S. R. Hatton, Hatton, Christian S.R., Cooper, CD, Hatton Christian S. R., Lawrie, CH, Liggins Amanda P., Banham, Alison, Christopher D O Cooper, Hatton, CS, Banham, AH, Collins, GP, Charles H Lawrie, Pulford, K, Amanda P Liggins, Banham Alison H., Karen Pulford, Charles H. Lawrie, Amanda P. Liggins, Collins Graham P., Graham P Collins, Collins, Graham P., Alison H Banham, Christian S R Hatton, Lawrie Charles H., Cooper, Christopher D.O., Alison H. Banham   +34 more
core   +2 more sources

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.

PLoS ONE, 2023
T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn, Korakot Atjanasuppat, Kitipong Uaesoontrachoon, Parin Rattananon, Worapapar Treesuppharat, Suradej Hongeng, Usanarat Anurathapan   +6 more
doaj   +2 more sources